Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bamlanivimab

- PMLiVE

Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shows promise in fatty liver disease MASH

Metabolic dysfunction-associated steatohepatitis is the second most common contributor to liver transplantation in the US

- PMLiVE

Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts

The company is seeking approval of donanemab to treat patients with early stages of the disease

- PMLiVE

Eli Lilly gains rights to QurAlis’ neurodegenerative disease therapy in deal worth over $620m

The agreement gives the company global rights to QRL-204 and other UNC13A-targeting compounds

- PMLiVE

Eli Lilly commits further $6.5m to UNICEF for young people at risk of noncommunicable diseases

The new funding builds on the company’s initial commitment of $14.4m in 2022

- PMLiVE

Eli Lilly to invest additional $5.3bn totalling $9bn in US manufacturing sites

The investment will provide an additional 200 jobs and more than 5,000 construction jobs during development of the site

- PMLiVE

Eli Lilly shares positive late-stage results for mirikizumab in Crohn’s disease

Nearly one in every 100 people in the US are diagnosed with inflammatory bowel disease

- PMLiVE

Eli Lilly and Aktis enter $1bn partnership to develop anticancer radiopharmaceuticals

Lilly will gain rights to develop Aktis’ lead programme targeting a tumour-associated antigen

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin efsitora in type 2 diabetes

It is hoped that a once-weekly treatment option could lead to improved adherence

- PMLiVE

Eli Lilly shares positive late-stage results for lebrikizumab in atopic dermatitis

The study evaluated lebrikizumab in patients with moderate-to-severe AD and darker skin tones

- PMLiVE

Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas

Approximately 18,740 new cases of CLL have been diagnosed in the US this year

- PMLiVE

Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m

The partnership is aimed at discovering oral inhibitors of a PPI target selected by Lilly

- PMLiVE

Eli Lilly to expand injectable manufacturing capacity with new $2.5bn facility in Germany

The site is expected to be operational in 2027 and will employ up to 1,000 highly skilled workers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links